As the Australian market braces for the Reserve Bank's first interest rate decision of the year, investor sentiment remains cautious, with ASX 200 futures pointing to a lower open amid global economic uncertainties. In such a climate, growth companies with high insider ownership can offer a unique appeal; they often signal confidence from those closest to the business and may provide resilience against broader market fluctuations.
Name | Insider Ownership | Earnings Growth |
Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
Medallion Metals (ASX:MM8) | 13.8% | 67.5% |
Acrux (ASX:ACR) | 14.6% | 91.8% |
Emerald Resources (ASX:EMR) | 18.1% | 34.7% |
Newfield Resources (ASX:NWF) | 31.5% | 72.1% |
AVA Risk Group (ASX:AVA) | 15.8% | 77.3% |
Pointerra (ASX:3DP) | 23.8% | 126.4% |
Plenti Group (ASX:PLT) | 12.7% | 120.1% |
Findi (ASX:FND) | 35.8% | 111.4% |
Click here to see the full list of 95 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.
Let's dive into some prime choices out of the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Aurelia Metals Limited is an Australian company involved in the exploration and production of mineral properties, with a market capitalization of A$405.98 million.
Operations: The company's revenue is derived from its operations at the Peak Mine (A$207.34 million), Dargues Mine (A$102.36 million), and Hera Mine (A$0.20 million).
Insider Ownership: 23.2%
Revenue Growth Forecast: 10.6% p.a.
Aurelia Metals is trading significantly below its estimated fair value, suggesting potential undervaluation. The company is expected to achieve profitability within three years, with revenue growth projected at 10.6% annually, outpacing the Australian market average of 5.9%. Despite a low forecasted return on equity of 9.6%, insider ownership remains a positive indicator for alignment with shareholder interests. Upcoming Q2 2025 earnings results on January 29 may provide further insights into its financial trajectory.
Simply Wall St Growth Rating: ★★★★★☆
Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$1.32 billion.
Operations: The company generates revenue of A$103.23 million from the development, manufacturing, and commercialization of the NovoSorb technology.
Insider Ownership: 10.2%
Revenue Growth Forecast: 17.7% p.a.
PolyNovo's earnings are forecast to grow significantly at 38.2% annually, outpacing the Australian market's 12%. Despite revenue growth projections of 17.7% being below the desired threshold of 20%, they still surpass the market average of 5.9%. Insider activity shows more shares bought than sold recently, though not in substantial volumes. Trading at a notable discount to its estimated fair value, PolyNovo reported a promising A$59.9 million in revenue for H1 FY2025, up 22.8% year-over-year.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: PWR Holdings Limited specializes in the design, prototyping, production, testing, validation, and sale of cooling products and solutions across various international markets with a market cap of A$841.72 million.
Operations: The company's revenue segments include PWR C&R at A$41.98 million and PWR Performance Products at A$111.26 million.
Insider Ownership: 13.2%
Revenue Growth Forecast: 12% p.a.
PWR Holdings' earnings are projected to grow at 15.6% annually, surpassing the Australian market's 12% growth rate. Revenue is expected to increase by 12% per year, outpacing the market average of 5.9%, although below the ideal growth threshold of 20%. The company boasts high insider ownership with no significant recent insider trading activity. PWR's Return on Equity is forecasted to reach a robust 26.5% in three years, indicating strong financial health and operational efficiency.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ASX:AMI ASX:PNV and ASX:PWH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。